Vaccines against RNA Viruses

RNA viruses cause animal, human, and zoonotic diseases that affect millions of individuals, as is being exemplified by the devastating ongoing epidemic of the recently identified SARS-Cov-2. For years vaccines have had an enormous impact on overcoming the global burden of diseases. Nowadays, a vast...

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (166 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03640nam-a2200781z--4500
001 993546232504498
005 20231214133249.0
006 m o d
007 cr|mn|---annan
008 202105s2020 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000044451 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/69449 
035 |a (EXLCZ)995400000000044451 
041 0 |a eng 
100 1 |a Saiz, Juan Carlos  |4 edt 
245 1 0 |a Vaccines against RNA Viruses 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (166 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a RNA viruses cause animal, human, and zoonotic diseases that affect millions of individuals, as is being exemplified by the devastating ongoing epidemic of the recently identified SARS-Cov-2. For years vaccines have had an enormous impact on overcoming the global burden of diseases. Nowadays, a vast number of different approaches, from purified inactivated and live attenuated viruses, nucleic acid (DNA or RNA) based candidates, virus-like particles, subunit elements, and recombinant viruses are been employed to combat viruses. However, for many of them efficient vaccines are not yet available. This will probably change dramatically with the current Covid-19 pandemic, as a vast variety of vaccinology approaches are being tested against it, with hundreds of candidates under development, dozens of them already in clinical trials, a fact that is breaking records in vaccine development and implementation. This is becoming possible thanks to the enormous work carried out during years to have the bases for a quick response, even against unknown pathogens, in an impressive short time. Here, results obtained with different vaccine´s methodological approaches against human (HIV, HCV, HRV) animal (PRRSV, PEDV, FMDV, VHSV) and zoonotic (RVF, WNV), RNA viruses are presented by field experts. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a artificial protein 
653 |a polyepitope B- and T-cell HIV-1 immunogen 
653 |a epitopes of broadly neutralizing HIV-1 antibodies 
653 |a peptide mimic of discontinuous epitope 
653 |a immunogenicity 
653 |a birds 
653 |a vaccines 
653 |a West Nile virus 
653 |a flavivirus 
653 |a herd immunity 
653 |a porcine epidemic diarrhea virus 
653 |a RNA interference 
653 |a processivity factor 
653 |a intestine epithelial cells 
653 |a N gene 
653 |a rotavirus nanoparticle vaccine 
653 |a gnotobiotic pigs 
653 |a FMDV 
653 |a peptide vaccine 
653 |a single dose 
653 |a amount 
653 |a pig 
653 |a VHSV 
653 |a non-virion (NV) 
653 |a transcriptome profiling 
653 |a rainbow trout 
653 |a immune pathways 
653 |a Rift Valley fever virus (RVFV) 
653 |a modified vaccinia Ankara (MVA) 
653 |a cellular response 
653 |a neutralizing antibodies 
653 |a Gn Gc glycoproteins 
653 |a passive serum:virus transfer 
653 |a hepatitis C virus 
653 |a neutralising antibodies 
653 |a animal models 
653 |a immune responses 
653 |a PRRSV Mosaic T-cell DNA vaccine VACV 
653 |a PRRS 
653 |a cross protection 
653 |a heterologous virus challenge 
776 |z 3-03943-623-6 
776 |z 3-03943-624-4 
700 1 |a Saiz, Juan Carlos  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:48:25 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338192340004498&Force_direct=true  |Z 5338192340004498  |b Available  |8 5338192340004498